OMG!!!! We are in big trouble in the Alzheimer's Division!

[anonymous]

No way this drug gets approved without more studies

See you on the soup line!!!!!!!!

 

[anonymous]

Based on their education level, all reps should be paid 60k a year, if that. Go get an MD, JD or at minimum MBA if you want to make real money.

WHAT A STUPID COMMENT, GET AN MD OR JD

And how much debt will you take on the possibly get a job 4 years from now? Know plenty of JD who are working shit jobs or cant find a good firm. those who go back to school at a later age will have shit opportunities unless they venture our on their own.
Get an MD, how stupid? to work in 10 years? When we have socialized medicine and you will work for a large govt institution that pays what a rep pays now? Try getting a job at the hospital when you are in your late 30s
MBA, unless its from an ivy league school its shit. I work with plenty of MBA in pharma who do the same job i do. And I dont have the debt they have.

 

[anonymous]

not sure why anyone is wasting their time speculating on the approval, you will know everything you need to know on Nov 6 when the committee meets, til them relax!!

 

[anonymous]

WHAT A STUPID COMMENT, GET AN MD OR JD

And how much debt will you take on the possibly get a job 4 years from now? Know plenty of JD who are working shit jobs or cant find a good firm. those who go back to school at a later age will have shit opportunities unless they venture our on their own.
Get an MD, how stupid? to work in 10 years? When we have socialized medicine and you will work for a large govt institution that pays what a rep pays now? Try getting a job at the hospital when you are in your late 30s
MBA, unless its from an ivy league school its shit. I work with plenty of MBA in pharma who do the same job i do. And I dont have the debt they have.

Very few in upper management have just a bachelors and/or a shitty 1 year masters degree. If you want to be a grunt just a 4 year degree is fine, but beyond that a terminal degree is the price of admission. Not saying it is sufficient, but it is usually required. Don’t be insecure.

 

[anonymous]

Definitely Very sizable layoffs across the board. R&D will get hit harder than what most people would expect. They’re very bottom-heavy with many Phase 1 studies and very little to no active or soon to start up studies in Phase 2 or 3.

Buyout would normally seem logical but it’s very iffy. Any company interested will want to let another quarter or two pass to see how Spinrazza holds up against the Roche SMA drug hitting the market and as insurance companies pick up/agree to coverage. Tysabri had yet another price hike this past spring so it muddled the sales figures this past quarter. They should be slipping with competition, but price hikes are hiding the slippage.

In short, major layoffs all over soon after a No vote, potential buyout not happening until late Q3/Q4 2021, followed by more cuts. Anyone buying Biogen will only want to keep its research team (labs & scientists, not clinical trial operations) in Cambridge and use it as a beachhead or base of operations in Kendall Square

If a NO vote, this outcome is very very likely.

And if the HR trolls don’t like the speculation, go tell the Execs they should have bought a company with late stage assets with at least 1 drug with blockbuster potential in the last 3 years, and not an eye care company with low revenue potential and early phase/pre-clinical deals that are 10+ years out. They dithered and now there is price to pay for that